Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer 
Patients with EGFR/MET Gene Abnormalities: A Single Center’s Experience

Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer 
Patients with EGFR/MET Gene Abnormalities: A Single Center’s Experience

Background and objective Epidermal growth factor receptor (EGFR) and cellular-mesenchymal to epithelial transition factor (c-Met) are widely expressed on cancer cells. There is a synergistic effect of EGFR and HGF/c-Met pathways on proliferation, downstream activation of signal transduction and an a...

Full description

Bibliographic Details
Main Authors: Jingjing WANG, Yujia CHI, Hanxiao CHEN, Bo JIA, Xiaoyu ZHAI, Menglei MA, Jianjie LI, Minglei ZHUO
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2022-07-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
egfr
met
target therapy
amivantamab
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.26

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.26

Similar Items